Introduction
Retinoids are regulators of cellular proliferation and differentiation. 1 Natural retinoids such as all-trans retinoic acid (ATRA) are currently used as chemopreventive and therapeutic agents in human cancers, particularly acute promyelocytic leukemia (APL). [2] [3] [4] Unfortunately, the use of natural retinoids is limited by side effects and acquired in vitro and in vivo resistance after prolonged exposure. 5 Therefore, synthetic retinoid analogs that couple increased specificity and reduced toxicity have been developed. 6 N-(4-hydroxyphenyl)retinamide (HPR) is a synthetic analog of ATRA that inhibits growth of many human cell lines, including many ATRA-resistant ones. 7 HPR effects are mediated through both retinoic acid receptor (RAR)-dependent and -independent mechanisms. 8 This drug can be maintained at high plasma levels of more than 3 mM for several years with minimal side effects. 9 Hence, HPR is currently tested as a chemopreventive and a therapeutic agent in several human malignancies such as breast, ovarian, cervical, and head and neck cancers. [10] [11] Adult T-cell leukemia/lymphoma (ATL) is an aggressive malignancy of activated T cells associated with human T-cell lymphotropic virus type I (HTLV-I) infection. 12 ATL carries a poor prognosis due to chemotherapy resistance. Important advances in ATL therapy were achieved with the combination of zidovudine and interferon (IFN), [13] [14] but the high relapse rate stresses the need for complementary therapies. 15 Recently, promising results were obtained with the combination of arsenic trioxide with IFN [16] [17] [18] or with ATRA. 19 Since most HTLV-Ipositive cells are resistant to ATRA [20] [21] and HPR was recently shown to inhibit growth of several HTLV-I-negative malignant T cells [20] [21] [22] , we investigated the effects of HPR on HTLV-Itransformed cells.
In this report, we demonstrate that, at clinically achievable concentrations, HPR is a potent and selective inducer of G 1 cell cycle arrest and apoptosis in HTLV-I-positive and HTLV-Inegative malignant T cells with no effect on normal T lymphocytes. HPR-mediated cell growth inhibition was associated with ceramide accumulation and caspase-mediated apoptosis in HTLV-I-negative cells only, and early degradation of p21, downregulation of cyclin D 1 , and upregulation of bax proteins in HTLV-I-positive cells only. These results place HPR as a potentially effective drug for the treatment of ATL and other HTLV-I-negative peripheral T-cell malignancies (PTCL).
Materials and methods

Cells, drugs and antibodies
The HTLV-I-transformed CD4 þ T-cell lines HuT-102, MT-2, C91PL, and C8166; and the HTLV-I-negative CD4 þ T-cell lines CEM, Jurkat, HuT-78, and MOLT-4 were grown as previously described. 17 Peripheral blood mononuclear cells were collected from two healthy HTLV-I-negative donors after obtaining their informed consent, and centrifuged over Ficoll-Hypaque (Lymphoprep, Nyegaard, Norway). Before HPR addition, cells were cultured for 24 h at 1 Â 10 5 cells/ml in RPMI-1640 medium containing 10% fetal calf serum (FCS) (Gibco, Invitrogen, Paisley, UK) and antibiotics. Activated PBMC were grown in Ham's F10 medium (Gibco) supplemented with 2% PHA (Gibco). When indicated, MolT-4 cells were transfected with either pSG5-Tax or empty vector using Lipofectamine plus s (Gibco) according to the manufacturer's recommendations.
ALTR and HPR (both purchased from Sigma Chemical Co, St Louis, MO, USA) were prepared as stock solutions in dimethylsulfoxide (DMSO) at 3 Â 10 À2 and 1 Â 10 À2 M, respectively, and stored in amber tubes at À801C. The final concentration of DMSO never exceeded 0.1% and this concentration showed no effect on the proliferation of all tested cell lines (data not shown). All experiments using ATRA or HPR were performed under yellow light (l4500 nm) to prevent photoisomerization. The general caspase inhibitor zVAD (Bachem Bioscience, King of Prussia, PA, USA) was dissolved in DMSO and used at concentrations ranging from 50 to 100 mM.
Antibodies: Rabbit polyclonal antibodies raised against p21, cyclin D 1 , bcl-2, bcl-X s/L , bax, PARP, and caspase 3 were obtained from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Mouse monoclonal anti-glyceraldehyde-phosphodehydrogenase (GAPDH) was obtained from Biogenesis (Stinford Fload, UK). Rabbit polyclonal anti-p53 was purchased from Chemicon International (Temecula, CA, USA). Mouse monoclonal anti-Tax (168-A51) was obtained from the NIH AIDS Research and Reagent Program.
Growth and cytotoxicity assays
Cell growth was assessed by the incorporation of 3 H-thymidine (Amersham Pharmacia Bioteck UK, Buckinghamshire, UK), cell count using trypan blue dye exclusion protocols and the use of the CellTiter 96 s nonradioactive cell proliferation assay kit (Promega Corp., Madison, WI, USA), as previously described. 23 Cells were grown in 96-well plates (Nunc, Naperville, IL, USA), and drugs were added at the indicated concentrations at the initiation of cultures for 24, 48, or 72 h. The results are expressed as cell growth relative to DMSO-treated controls and are derived from the mean of quadruplicate wells. The results are representative of at least three independent experiments. Similar trends were observed with the trypan blue dye exclusion and the use of the CellTiter 96 s nonradioactive cell proliferation assays. Cellular cytotoxicity was assessed using the CytoTox 96 s nonradioactive cytotoxicity assay kit as suggested by the manufacturer (Promega Corp.). The results are expressed as cytotoxicity relative to maximum values and are derived from the mean of quadruplicate wells from at least two independent experiments.
Cell cycle analysis
Cells cultured in six-well plates, for 24, 48, or 72 h post-HPR treatment, were washed twice with cold phosphate-buffered saline (PBS), fixed in ice cold 100% ethanol, and stored for 24 h at 41C. Subsequently, cells were rinsed with PBS, incubated for 1 h in Tris-HCl buffer (pH 7.4) containing 50 U RNase A and then stained with propidium iodide (PI) (50 mg/ml) (Sigma). Cell cycle analysis was performed using a FACScan flow cytometer (Becton Dickinson, San Jose, CA, USA). Each sample was collected as 10 000 ungated events and the corresponding cell cycle distribution (including apoptosis) was determined using Modfit software (Becton-Dickinson). The results are representative of two independent experiments.
TUNEL assay
The terminal deoxy-transferase (TdT)-mediated deoxyuridine triphosphate (dUTP) nick-end labeling (TUNEL) assay was used to monitor the extent of DNA fragmentation due to apoptosis. The assay was performed according to the manufacturer's suggestions (Boehringer, Mannheim, Germany). Fluoresceinconjugated dUTP incorporated in nucleotide polymers was detected and quantified using flow cytometry. Approximately 10 000 cells per sample were acquired and analyzed using CellQuest software (Becton-Dickinson). The results are representative of two independent experiments.
Caspase activation assays
Caspase activity was measured using the ApoTarget Caspase Colorimetric Assay Sampler Kit (Biosource International, CA, USA), according to the manufacturer's instructions. We detected caspase activity by measuring the cleavage of synthetic substrates upon their incubation with lysates of apoptotic cells. These former substrates contain tetrapeptide sequences mimicking the cleavage site of the various substrate subgroups. Caspases 3, 8, and 9 activities were assayed by OD measurement at 405 nm using an ELISA microplate reader. The results are representative of two independent experiments.
Measurement of mitochondrial membrane potential
Quantitation of mitochondrial membrane potential was determined by rhodamine (R123) retention. R123 is a cationic fluorescent dye that accumulates in active mitochondria with high membrane potentials. HPR-treated cells were washed twice in 130 mM NaCl, 5 mM KCl, 1 mM Na 2 HPO 4 , 1 mM CaCl 2 , 1 mM MgCl 2 , and 25 mM Hepes buffer (pH 7.4) and were, then, loaded with 5 mM R123 (Sigma) for 30 min at 371C. Subsequently, cells were washed twice with the former buffer. R123 was excited at 488 nm, and fluorescence emission at 525 nm was assessed using flow cytometry. The results were analyzed using the CellQuest software. The results are representative of two independent experiments.
Immunoblot analysis
Protein lysates (0.25 M. Tris-HCl (pH 7.4), 20% b-mercaptoethanol, and 5% SDS) were prepared from treated and untreated cells at 41C. Protein concentrations were determined using the DC protein assay (Bio-Rad Laboratories, Hercules, CA, USA). Total cellular proteins were boiled and loaded (30 mg/lane) onto a 10% SDS-polyacrylamide gel, subjected to electrophoresis, and transferred onto nitrocellulose membranes (Bio-Rad Laboratories). Protein quality and equal loading were assessed by Coomassie blue staining. The blots were blocked for 1 h at room temperature in 5% skimmed milk in TBS (50 mM Tris-HCl and 150 mM NaCl). The membranes were then probed overnight with primary antibody at 41C. Antibody binding to specific proteins was visualized by enhanced chemiluminescence using the ECL system (Amersham, Buchinghamshire, UK) with horseradish peroxidase-conjugated secondary antibody (Bio-Rad) at a 1:3000 dilution.
Ceramide measurement
Lipids were collected according to the method of Bligh and Dyer. 24 Ceramide was measured with a modified diacylglycerol kinase assay using external ceramide standards as described. 25 Briefly, 80% of the lipid sample was dried under N 2 . The dried lipid was solubilized in 20 ml of an octyl-b-D-glucoside/dioleoyl phosphatidylglycerol micellar solution (7.5% octyl-b-D-glucoside, 25 mM dioleoyl phosphatidylglycerol) by several cycles of sonication in a bath sonicator followed by resting at room temperature for 15À20 min. The reaction buffer was prepared as a 2 Â solution, containing 100 mM imidazole HCL, pH 6.6, 100 mM LiCl, 25 mM MgCl 2 , 2 mM EGTA. To the lipid micelles, 50 ml of 2 Â reaction buffer , 0.2 ml of 1 M dithiothreitol, 5 mg of diglycerol kinase membranes, and dilution buffer were added (10 mM imidazole, pH 6.6, 1 mM diethylenetriaminepentaacetic acid, pH 7) to a final volume of 90 ml. The reaction was started by adding 10 ml 2.5 mM [g-32 P]ATP solution (specific activity of 75 000-200 000 c.p.m./nmol). The reaction was allowed to proceed at 251C for 30 min. Bligh and Dyer lipid extraction was performed and a 1.5 ml aliquot of the organic phase was dried under N 2 . Lipids were then resuspended in a volume of 50 ml methanol/chloroform (1:9, v/v) and 25 ml was spotted on a 20 cm silica gel thin layer chromatography plate. Plates were developed with chloroform:acetone:methanol:acetic acid:H 2 O (50:20:15:10:5), air dried, and subjected to autoradiography. The radioactive spots corresponding to phosphatidic acid and ceramide-phosphate, the phosphorylated products of diacylglycerol and ceramide, respectively, were identified by comparison to known standards. Spots were scraped into a scintillation vial containing 4 ml of scintillation fluid and counted on a scintillation counter. Linear curves of phosphorylation were produced over a concentration range of 0-960 pM of external standards (dioleoyl glycerol and CIII ceramide, Sigma). Ceramide levels were always normalized to lipid phosphate levels. It is important to note that under these conditions, there was a total conversion of ceramide and diacylglycerol to their phosphorylated products, and there was no change in the specific activity of the diacylglycerol kinase enzyme.
Statistical analysis
Four statistical tests were performed to validate the significance of the observed results: the Fisher test, the Dunnett test, the twoway analysis of variance (ANOVA) test, and the two-sample t-test as described. 26 
Results
We used four HTLV-I-transformed cell lines: HuT-102, MT2, C8166, and C91PL; and three HTLV-I-negative T-cell lines:
CEM, Jurkat, and Molt-4. All cell lines with the exception of C8166 (Po0.01; Dunnett and ANOVA tests) and to a lesser extent CEM (Po 0.01; Dunnett test) are resistant to pharmacological levels of ATRA up to 5 mM (Figure 1 and data not shown).
HPR induces growth arrest of malignant but not of normal T cells HPR treatment at concentrations from 10
À9 to 10 À5 M resulted in a dose-and time-dependent growth inhibition of the eight tested cell lines (Figure 2a and data not shown). To study achievable plasma levels, HPR was subsequently used at concentrations ranging from 0.1 to 5 mM. HTLV-I-negative cells were more sensitive to HPR as compared to HTLV-I-positive cells (Po 0.01; Dunnett test) (Figure 2a ). Growth inhibition was first observed at 24 h and was almost complete by 72 h at 5 mM HPR in HTLV-Ipositive cells and at 1 mM in HTLV-I-negative cells. Interestingly, C8166, the only ATRA-sensitive cell line, was also the most sensitive to HPR among the HTLV-I-positive cells. Also, Taxtransfected Molt-4 cells, which express high levels of Tax protein as compared to HuT-102 cells, had a significantly reduced sensitivity to HPR (Po0.01; t-test) (Figure 2b ), indicating that Tax partially protects HTLV-I-infected cells against HPRmediated growth inhibition. No significant necrosis was observed in the various tested cell lines after 6 h of HPR treatment, ruling out direct cytotoxicity (data not shown). Most importantly, resting and PHA-stimulated normal T cells from two healthy donors were completely resistant to HPR treatment up to 10 mM concentrations (Figure 2c) .
HPR treatment causes G 1 cell cycle arrest and apoptosis in malignant T cells
To investigate the mechanisms involved in HPR-induced growth inhibition, cell cycle analyses were performed. Four representative cell lines (HuT-102, MT2, CEM, and Jurkat) were selected for the cell cycle analyses. No major variation in cell cycle distribution was observed between untreatred HuT-102, MT-2, CEM, and Jurkat cells at different time points (data not shown). HPR induced a significant increase in the apoptotic pre-G 1 region in all tested cell lines (Po 0.01; Dunnett test) (Figure 3a and data not shown). However, HPR effects were more pronounced in CEM and Jurkat cells reaching 31% at 24 h of treatment with a modest dose of HPR (0.5 mM), while higher doses (5 mM) and more prolonged exposure to HPR up to 48 h were required to induce significant apoptosis (40%) in HuT-102 and MT-2 cells (Figure 3a and data not shown).
To confirm the induction of apoptosis in HPR-treated malignant T cells, we used the TUNEL assay that shows DNA cleavage by labeling free 3 0 -OH ends. After 72 h of culture, the percentage of TUNEL-positive HuT-102 cells was 2% for the control cells and 24% for cells treated with 5 mM HPR (Figure 3b HPR-induced apoptosis was also associated with dissipation of mitochondrial membrane potential as shown by the decrease in rhodamine-123 fluorescence. This effect was evident at 24 h in all tested HTLV-I-negative cells at HPR concentrations of 0.5 and 5 mM, while a more moderate decrease was observed in HTLV-I-positive cells, only at the highest concentration (Figure 3c and data not shown) .
In addition to apoptosis induction, HPR treatment induced a moderate cell cycle arrest, since the number of cycling cells significantly diminished from 52 to 33% with 1 mM HPR treatment of CEM cells and from 53 to 43% with 5 mM HPR treatment of HuT-102 cells (Po 0.01; Dunnett test) (Figure 3a) . Jurkat and MT2 cells showed similar effects to CEM and HuT-102 cells, respectively (data not shown). Although induction of apoptosis likely plays the major role, cell cycle arrest also contributes to the drastic effects of HPR on growth of malignant T cells. 
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HPR-induced apoptosis is caspase dependent in HTLV-I-negative cells
HPR-induced loss in mitochondrial membrane potential may result in the activation of the caspase cascade 27 , particularly in HTLV-I-negative cells. Indeed, HPR-induced apoptosis was associated with caspase activation, as shown by PARP cleavage (113 kDa) into its death-associated fragments (89 and 24 kDa). This cleavage was clearly observed after 24 h at 0.5 mM HPR for CEM and Jurkat cells, and at 5 mM for HuT-102, MT-2, and C8166 cells (Figure 4a and data not shown). Furthermore, HPR treatment resulted in caspase 3 cleavage (Figure 4a (Table 1) . Interestingly, HPR-induced growth inhibition of HuT-102 cells was not reversed by the general caspase inhibitor zVAD (Figure 4c ), despite reversal of PARP cleavage (Figure 4d ), while that of CEM cells was partially but significantly reversed from 13 to 24% (Po 0.05) at 0.5 mM and from 0 to 22% (Po0.05) at 1 mM HPR concentration (Figure 4c) . Altogether, these results demonstrate the involvement of caspase activation in HPR-induced growth arrest in HTLV-I-negative cells only.
HPR-induced ceramide accumulation in HTLV-I-negative cells
We, then, investigated the cellular pathways involved in HPRinduced cell cycle arrest and apoptosis. Similar to previous reports, 22 treatment of HTLV-I-negative cells with HPR for 24 h resulted in approximately six-fold induction of ceramide levels in HPR-treated (1 mM) CEM cells (Po0.05; t-test) and approximately four-fold induction of ceramide levels in HPR-treated (3 mM) Jurkat and Molt-4 cells (Po 0.05; t-test), as compared to DMSO-treated control cells (Figure 5a and data not shown) . Interestingly, no significant increase in ceramide levels was observed after 24 h in HPR-treated (5 mM) HuT-102, C8166, and MT2 cells (Figure 5a and data not shown), implicating the ceramide pathway in HPR-induced growth arrest of HTLV-Inegative cells only.
HPR upregulated bax downregulated p21 and cyclin D 1 in HTLV-I-positive cells
As previously reported [28] [29] [30] , bcl-2, bcl-X L , and p53 protein levels were not affected by HPR treatment in any of the tested (Figure 6a and 6b) . HPR-induced downregulation of p21 protein level was secondary to proteasome-mediated degradation because it was reversed by the proteasome inhibitor zLLL but not the caspase inhibitor zVAD (Figure 6c) . A secondary increase in p21 protein levels was observed after 24 h of HPR treatment of HTLV-I-positive cells (Figure 6b ) and may be explained by the well-known upregulation of p21 expression during apoptosis and senescence. [31] [32] In contrast, HPR treatment (1 mM) of the HTLV-I-negative cells, CEM and Jurkat, had no effect on cyclin D 1 and p21 protein levels (data not shown).
Altogether, these results demonstrate a different mechanism of action of HPR in HTLV-I-positive and HTLV-I-negative cells.
Discussion
We show that clinically achievable concentrations of HPR induce growth inhibition, G 1 -arrest and apoptosis in all tested HTLV-I-transformed and HTLV-I-negative T cells, including ATRA-resistant cells. The larger spectrum of HPR as compared to ATRA may be explained by the fact that ATRA effects are mediated solely by the RARs, while HPR may function through both RAR-dependent and -independent mechanisms. 8 Most importantly, and similar to recent reports, 22 ,30 no effect of HPR was observed on resting and stimulated normal T lymphocytes. The mechanism for this exquisite sensitivity of transformed cells to HPR remains to be elucidated.
Some studies have suggested the involvement of bcl-2, 28 caspases, [33] [34] ceramide, [35] [36] [37] and oxygen radical species 30, 37 in HPR-mediated apoptosis. Here, we show a similar mechanism of action in HTLV-I-negative cells, where HPR-induced apoptosis was associated with ceramide accumulation and caspasemediated cell death. In these cells, HPR treatment resulted in a significant loss of mitochondrial membrane potential, rapid and important ceramide accumulation, and activation of the caspase cascade, implicating caspases 3, 8, and 9, and resulting in complete PARP cleavage. Importantly, HPR-induced growth inhibition was partially but significantly reversed by zVAD implicating caspase-mediated cell death in HPR-induced apoptosis of HTLV-I-negative cells.
In contrast, a completely different mechanism of action of HPR was observed in HTLV-I-positive cells. In these cells, HPR treatment had no significant effect on ceramide levels but resulted in a more moderate loss of mitochondrial membrane potential, which may likely explain caspase 9 activation. However, no further activation of caspase 8 or 3 was observed, and HPR-induced growth inhibition was not reversed by zVAD, suggesting a caspase-independent mechanism of cell death in HPR-induced apoptosis of HTLV-I-positive cells. The fact that HTLV-I-negative cells are more sensitive than their HTLV-Ipositive or Tax-transfected counterparts to HPR effects suggests that Tax or Tax-induced constitutive activation of the NF-kB pathway 38 may protect HTLV-I-transformed cells from caspasedependent apoptosis and may prevent ceramide accumulation. Interestingly, HPR treatment significantly downregulated Tax protein levels in C8166 cells only (data not shown), which may explain the higher sensitivity of this cell line to HPR effects as compared to other HTLV-I-positive cells. On the other hand, in HTLV-I-positive cells only, HPR treatment rapidly induced a proteasomal-mediated degradation of p21 whose expression is upregulated at both the transcript and protein levels in HTLV-Iinfected cells, as Tax transactivates the p21 promoter. 39, 40 Furthermore, p21 was recently shown to prevent apoptosis and to stimulate the growth of HTLV-I-positive cells. 41 Hence, the À6 M HPR for 6 h in the absence or presence of z-VAD (100 mM) or zLLL (50 mM). Whole SDS protein lysates (50 mg/lane) were prepared and immunoblotted against p21 antibody and reprobed against GAPDH to ensure equal protein loading.
early HPR-induced downregulation of p21 in HTLV-I-positive cells may contribute to HPR-induced cell cycle arrest due to the removal of this antiapoptotic and mitogenic factor in Taxexpressing cells. Moreover, HPR-induced downregulation of cyclin D 1 and upregulation of bax protein levels in HPR-treated HTLV-I-positive cells only likely contributes to the observed HPR-mediated G 1 arrest and cell death in these cells. Finally, the secondary increase of p21 at 24 h could be explained by the well-known induction of p21 during apoptosis and senescence. 39, 40 In conclusion, despite a differential sensitivity to HPR and a completely different mechanism of action in HTLV-I-negative cells vs HTLV-I-positive cells, clinically achievable concentrations of HPR caused a dramatic inhibition of cell proliferation, G 1 cell cycle arrest, and massive apoptosis in both cell types. ATL remains of poor prognosis and a challenge to clinicians. 12 Novel effective drugs are warranted to reduce the emergence of resistant clones. In addition, HTLV-I-negative PTCL are also associated with poor prognosis due to a lower response rate to anthracyclin-based combination chemotherapy and a higher relapse rate as compared to B-cell lymphomas. 42 Retinoids are potentially promising for ATL or PTCL therapy, 43 ,44 yet most tested malignant T cells are resistant to ATRA. The efficacy of HPR in inhibiting growth of ATRA-resistant HTLV-I-positive and negative malignant T cells, but not of resting or activated normal T lymphocytes, places HPR as a potentially effective drug for the induction and/or maintenance therapy of ATL and PTCL.
